New drugs and diagnostic methods should be safe and ideally available quickly—but the preclinical test phase in particular often slows down rapid progress due to the high level of resources required.

The development of radioactive marker substances (“radiotracers”) in particular, which make physiological and pathological processes in the body visible and can be used in cancer diagnostics, for example, requires time-consuming and cost-intensive tests that have often been based on animal experiments to date.

However, these are not only ethically controversial, but often provide results that are not transferable to the human body.